← SynDRA
FENEBRUTINIB
SynDRA canonical compound SYN0039231 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | BTK |
|---|
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- BTK INHIBITOR
- Tyrosine-protein kinase BTK inhibitor
- Bruton's tyrosine kinase (BTK) inhibitor
Cross-references
Synonyms
- GDC-0853
- G-02599853
- G02599853
- RG-7845
- RG7845
- RO-7010939
- RO7010939
- GDC 0853
- GDC0853
- E9L2885WUL
- fenebrutinibum
- RefChem:598867
- Bruton Tyrosine Kinase Inhibitor GDC-0853
- Fenebrutinib (GDC-0853)
- Fenebrutinib [INN]
- Fenebrutinib [USAN]
- GDC-0853(RG7845)
- 9AJ
- Fenebrutinib (USAN/INN)
- Fenebrutinib [USAN:INN]
- UNII-E9L2885WUL
- FENEBRUTINIB [WHO-DD]
- GTPL9299
- orb1296105
- SCHEMBL14912882
- SCHEMBL29369328
- SCHEMBL29429358
- CHEBI:234073
- C37H44N8O4
- GLXC-10689
- EX-A1308
- JHC04834
- BDBM50244440
- NSC798202
- s8421
- AKOS032945119
- FENEBRUTINIB ( GDC-0853 )
- CS-5927
- NSC-798202
Look up FENEBRUTINIB in the interactive SynDRA portal →